demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 prophylaxis (excluding children)
bamlanivimab monotherapy BLAZE-2 US ...

0 studies excluded by filtering options 0